Author

V. Ueckermann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:human· 4 Assay:proteomics· 2

Frequent Co-Authors

M. Boswell· 4 shared P. Kgagudi· 3 shared P. Moore· 3 shared T. Rossouw· 3 shared A. Bodenstein· 2 shared B. E. Lambson· 2 shared B. Lambson· 2 shared B. Oosthuysen· 2 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

M. Boswell

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

SARS-CoV-2 BA.4 infection triggers more cross-reactive neutralizing antibodies than BA.1

S. Richardson, T. Motlou, M. van der Mescht, B. Lambson, J. Everatt, D. Amoako, A. Van Gottberg, N. Wolter, Z. de Beer, T. Roma de Villiers, A. Bodenstein, G. van den Berg, T. M. Rossouw, M. Boswell, V. Ueckermann, , P. Moore

This study compares the neutralizing antibody responses to SARS-CoV-2 BA.4 and BA.1, finding BA.4 induces more cross-reactive antibodies, suggesting potential benefits for next-generation vaccines.

bioRxiv · Jul 14, 2022 · PreprintImmunology

Fc effector activity and neutralization against SARS-CoV-2 BA.4 is compromised in convalescent sera, regardless of the infecting variant

S. Richardson, P. Kgagudi, N. P. Manamela, H. Kaldine, E. Venter, T. Pillay, B. E. Lambson, M. van der Mescht, T. Hermanus, Z. de Beer, T. de Villier, A. Bodenstein, G. van den Berg, M. du Pisanie, W. Burgers, , P. Moore

This study shows that convalescent sera and post-vaccination breakthrough infections have reduced neutralization and ADCC activity against SARS-CoV-2 BA.4, despite prior infection with different variants.

bioRxiv · Jul 14, 2022 · PreprintImmunology

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies

T. Moyo-Gwete, M. Madzivhandila, Z. Makhado, F. Ayres, D. Mhlanga, B. Oosthuysen, B. Lambson, P. Kgagudi, H. Tegally, A. Iranzadeh, D. Doolabh, L. Tyers, L. Chinhoyi, M. Mennen, S. Skelem, , P. Moore

This study examines antibody responses to the SARS-CoV-2 501Y.V2 variant in patients hospitalized in early 2021, finding robust cross-reactivity against earlier variants and the 501Y.V3 variant.

bioRxiv · Mar 6, 2021 · PreprintImmunology

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

C. K. Wibmer, F. Ayres, T. Hermanus, M. Madzivhandila, P. Kgagudi, B. Oosthuysen, B. E. Lambson, T. de Oliveira, M. Vermeulen, K. van den Berg, T. Rossouw, M. Boswell, V. Ueckermann, S. Meiring, A. von Gottberg, , P. L. Moore

This study shows that SARS-CoV-2 501Y.V2 pseudovirus escapes neutralization by South African convalescent plasma but not binding, suggesting potential for reinfection and reduced vaccine efficacy.

bioRxiv · Jan 18, 2021Immunology